Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple threat: immunotherapy plus chemo and radiation takes on head and neck cancer

NCT ID NCT07447570

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiotherapy can improve outcomes for people with locally advanced head and neck cancer. The study will enroll 27 participants and track how many remain cancer-free after one year. The approach aims to boost the immune system's ability to fight the cancer while using radiation and chemotherapy to shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Iparomlimab and tuvonralimab (immunotherapy drugs) plus chemotherapy (cisplatin) and radiation therapy
What this could lead to
If successful, this combination could offer a more effective treatment for advanced head and neck cancer, potentially lowering the chance of the cancer coming back.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination of immunotherapy, chemotherapy, and radiation may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-PD-1/CTLA-4 ANTIBODY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-PD-1/CTLA-4 ANTIBODY HEAD AND NECK CANCER RADIOTHERAPY

Contacts and locations

Locations

  • Second Affiliated Hospital Of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.